Quick Answer
Coherus Oncology, Inc. reported Operating Income Loss of -$181.13 million for the year ending 2025.
- Coherus Oncology, Inc. showed an increase of +9.3% in Operating Income Loss from 2024 to 2025.
- This data is from Coherus Oncology, Inc.'s annual report (Form 10-K), filed with the SEC on March 9, 2026.
- XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2013: -$6.78 million | Q1 2014: -$13.76 million | Q2 2014: -$17.94 million | Q3 2014: -$6.42 million | Q1 2015: -$36.75 million | Q2 2015: -$58.90 million | Q3 2015: -$71.22 million | Q1 2016: -$64.35 million | Q2 2016: -$62.74 million | Q3 2016: $84.62 million | Q1 2017: -$72.42 million | Q2 2017: -$56.64 million | Q3 2017: -$56.62 million | Q1 2018: -$42.03 million | Q2 2018: -$44.91 million | Q3 2018: -$56.97 million | Q1 2019: -$16.60 million | Q2 2019: $27.49 million | Q3 2019: $51.84 million | Q1 2020: $40.87 million | Q2 2020: $65.31 million | Q3 2020: $33.72 million | Q1 2021: -$167.36 million | Q2 2021: -$24.16 million | Q3 2021: -$32.79 million | Q1 2022: -$80.93 million | Q2 2022: -$44.01 million | Q3 2022: -$80.45 million | Q1 2023: -$67.75 million | Q2 2023: -$34.54 million | Q3 2023: -$32.01 million | Q1 2024: -$67.79 million | Q2 2024: -$39.63 million | Q3 2024: -$46.86 million | Q1 2025: -$45.44 million | Q2 2025: -$45.49 million | Q3 2025: -$44.33 million.
- Over the full 14 years of available data (2012 to 2025), Coherus Oncology, Inc.'s Operating Income Loss has declined by 370.3%.
- Historical annual values: Fiscal year 2025: -$181.13 million | Fiscal year 2024: -$199.65 million | Fiscal year 2023: -$203.20 million | Fiscal year 2022: -$256.88 million | Fiscal year 2021: -$263.86 million | Fiscal year 2020: $156.32 million | Fiscal year 2019: $107.77 million | Fiscal year 2018: -$204.42 million | Fiscal year 2017: -$232.14 million | Fiscal year 2016: -$115.93 million | Fiscal year 2015: -$219.07 million | Fiscal year 2014: -$64.68 million | Fiscal year 2013: -$35.99 million | Fiscal year 2012: -$38.52 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: